FindTrial
Sign In

A database study to investigate treatment status of carfilzomib after daratumumab in multiple myeloma using Millennial Medical Record

A database study to investigate treatment status of carfilzomib after daratumumab in multiple myeloma using Millennial Medical Record

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1050250062
Enrollment
Unknown
Registered
2025-07-04
Start date
2025-07-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

None listed

Sponsors

Kinoshita Keita
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: In Millennial Medical Records, patients who were prescribed daratumumab after a diagnosis of multiple myeloma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Treatment patterns after daratumumab Efficacy and safety of carfilzomib in patients with exposure to daratumumab—

Secondary

MeasureTime frame
The efficacy of carfilzomib in patients who have received prior daratumumab treatment, and its association with patient background at the start of initial carfilzomib Safety of carfilzomib in patients with prior daratumumab treatment, and its association with patient background at the start of initial carfilzomib Characteristics of the population in which proteasome inhibitors are selected after daratumumab Reasons for selecting carfilzomib after daratumumab—

Contacts

Public ContactHisahiro Hishinuma

ONO PHAMACEUTICAL CO., LTD.

h.hishinuma@ono-pharma.com+81-6-6263-5670

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026